Search Results - Vipin Arora

  • Showing 1 - 14 results of 14
Refine Results
  1. 1
    Cold Atmospheric Plasma (CAP) In Dentistry

    Cold Atmospheric Plasma (CAP) In Dentistry by Vipin Arora

    Published 2013
    Get full text
    Artigo
    Save to List
    Saved in:
  2. 2
    Banking Stem Cells from Human Exfoliated Deciduous Teeth (SHED): Saving for the Future

    Banking Stem Cells from Human Exfoliated Deciduous Teeth (SHED): Saving for the Future by Vipin Arora, Pooja Arora, AK Munshi

    Published 2009
    Get full text Get full text
    Revisão
    Save to List
    Saved in:
  3. 3
    Sesamol Suppresses Neuro-Inflammatory Cascade in Experimental Model of Diabetic Neuropathy

    Sesamol Suppresses Neuro-Inflammatory Cascade in Experimental Model of Diabetic Neuropathy by Kanwaljit Chopra, Vinod Tiwari, Vipin Arora, Anurag Kuhad

    Published 2010
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  4. 4
    Fight fire with fire: Neurobiology of capsaicin-induced analgesia for chronic pain

    Fight fire with fire: Neurobiology of capsaicin-induced analgesia for chronic pain by Vipin Arora, James N. Campbell, Man‐Kyo Chung

    Published 2020
    Get full text
    Revisão
    Save to List
    Saved in:
  5. 5
    Ablation of TRPV1+ Afferent Terminals by Capsaicin Mediates Long-Lasting Analgesia for Trigeminal Neuropathic Pain

    Ablation of TRPV1+ Afferent Terminals by Capsaicin Mediates Long-Lasting Analgesia for Trigeminal Neuropathic Pain by Sheng Wang, Chao Bian, Jiale Yang, Vipin Arora, Yiwei Gao, Wei Feng, Man‐Kyo Chung

    Published 2020
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  6. 6
    Incorporating patient experience into drug development for ulcerative colitis: development of the Urgency Numeric Rating Scale, a patient-reported outcome measure to assess bowel urgency in adults

    Incorporating patient experience into drug development for ulcerative colitis: development of the Urgency Numeric Rating Scale, a patient-reported outcome measure to assess bowel u... by Marla C. Dubinsky, Peter M. Irving, Remo Panaccione, April N. Naegeli, Alison Potts-Bleakman, Vipin Arora, Mingyang Shan, Simon Travis

    Published 2022
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  7. 7
    Efficacy and safety of mirikizumab in psoriasis: results from a 52-week, double-blind, placebo-controlled, randomized withdrawal, phase III trial (OASIS-1)

    Efficacy and safety of mirikizumab in psoriasis: results from a 52-week, double-blind, placebo-controlled, randomized withdrawal, phase III trial (OASIS-1) by Andrew Blauvelt, Alexa B. Kimball, Matthias Augustin, Yukari Okubo, Michael M. Witte, Claudia Rodriguez Capriles, Angelina Sontag, Vipin Arora, Olawale Osuntokun, Bruce Strober

    Published 2022
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  8. 8
    Central Reading of Ulcerative Colitis Clinical Trial Videos Using Neural Networks

    Central Reading of Ulcerative Colitis Clinical Trial Videos Using Neural Networks by Klaus Gottlieb, James Requa, William E. Karnes, Ranga Chandra Gudivada, Jie Shen, Efren Rael, Vipin Arora, Tyler Dao, Andrew Ninh, James M. McGill

    Published 2020
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  9. 9
    Efficacy and safety of adalimumab in Japanese patients with moderately to severely active ulcerative colitis

    Efficacy and safety of adalimumab in Japanese patients with moderately to severely active ulcerative colitis by Yasuo Suzuki, Satoshi Motoya, Hiroyuki Hanai, Takayuki Matsumoto, Toshifumi Hibi∥, Anne Robinson, Nael M. Mostafa, Jingdong Chao, Vipin Arora, Anne Camez, Roopal Thakkar, Mamoru Watanabe

    Published 2013
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  10. 10
    Extended Induction and Prognostic Indicators of Response in Patients Treated with Mirikizumab with Moderately to Severely Active Ulcerative Colitis in the LUCENT Trials

    Extended Induction and Prognostic Indicators of Response in Patients Treated with Mirikizumab with Moderately to Severely Active Ulcerative Colitis in the LUCENT Trials by Geert D’Haens, Peter Higgins, Laurent Peyrin–Biroulet, Bruce E. Sands, Scott D. Lee, Richard Moses, Isabel Redondo, Rodrigo Escobar, Theresa Hunter, Anthony Keohane, Nathan Morris, Xin Zhang, Vipin Arora, Taku Kobayashi

    Published 2024
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  11. 11
    Efficacy and Safety of Continued Treatment With Mirikizumab in a Phase 2 Trial of Patients With Ulcerative Colitis

    Efficacy and Safety of Continued Treatment With Mirikizumab in a Phase 2 Trial of Patients With Ulcerative Colitis by William J. Sandborn, Marc Ferrante, Bal Raj Bhandari, Elina Berliba, Toshifumi Hibi∥, Geert D’Haens, Jay Tuttle, Kathryn A. Krueger, Stuart Friedrich, M. Durante, Vipin Arora, April N. Naegeli, Jochen Schmitz, Brian G. Feagan

    Published 2020
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  12. 12
    Adalimumab for the Treatment of Japanese Patients With Intestinal Behçet’s Disease

    Adalimumab for the Treatment of Japanese Patients With Intestinal Behçet’s Disease by Satoshi Tanida, Nagamu Inoue, Kiyonori Kobayashi, Makoto Naganuma, Fumihito Hirai, Bunei Iizuka, Kenji Watanabe, Keiichi Mitsuyama, Takuya Inoue, Yoshiaki Ishigatsubo, Yasuo Suzuki, Masakazu Nagahori, Satoshi Motoya, Shirô Nakamura, Vipin Arora, Anne Robinson, Roopal Thakkar, Toshifumi Hibi∥

    Published 2014
    Get full text
    Artigo
    Save to List
    Saved in:
  13. 13
    Mirikizumab as Induction and Maintenance Therapy for Ulcerative Colitis

    Mirikizumab as Induction and Maintenance Therapy for Ulcerative Colitis by Geert D’Haens, Marla C. Dubinsky, Taku Kobayashi, Peter M. Irving, Stefanie Howaldt, Juris Pokrotnieks, Kathryn A. Krueger, Janelle Laskowski, Xingyuan Li, Trevor Lissoos, Joe Milata, Nathan Morris, Vipin Arora, Catherine Milch, William J. Sandborn, Bruce E. Sands

    Published 2023
    Get full text
    Artigo
    Save to List
    Saved in:
  14. 14
    Two-Year Efficacy and Safety of Mirikizumab Following 104 Weeks of Continuous Treatment for Ulcerative Colitis: Results From the LUCENT-3 Open-Label Extension Study

    Two-Year Efficacy and Safety of Mirikizumab Following 104 Weeks of Continuous Treatment for Ulcerative Colitis: Results From the LUCENT-3 Open-Label Extension Study by Bruce E. Sands, Geert D’Haens, David B. Clemow, Peter M. Irving, Jordan Johns, Theresa Hunter, María T. Abreu, Scott D. Lee, Tadakazu Hisamatsu, Taku Kobayashi, Marla C. Dubinsky, Séverine Vermeire, Corey A. Siegel, Laurent Peyrin–Biroulet, Richard Moses, Joe Milata, Vipin Arora, Remo Panaccione, Axel Dignaß

    Published 2024
    Get full text Get full text
    Artigo
    Save to List
    Saved in:

Search Tools: